Administration of T cells targeting tumor associated antigens to patients with myeloma

      Allogeneic hematopoietic stem cell transplant (HSCT) remains the only curative immunotherapy for patients (pts) with multiple myeloma (MM). However, high rates of transplant-related mortality (~30%) limits the applicability of this approach. Thus, to separate the beneficial postHSCT “graft versus myeloma” effect from the antecedent toxicities, we developed a strategy to enrich autologous MM-specific T cells ex vivo by stimulating PBMCs with overlapping peptide libraries of 5 MM expressed tumor associated antigens (TAA), PRAME, SSX2, MAGEA4, NY-ESO1 and Survivin.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect